Key features and details
- Rabbit polyclonal to LATS2
- Suitable for: IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Product nameAnti-LATS2 antibody
See all LATS2 primary antibodies
DescriptionRabbit polyclonal to LATS2
Tested applicationsSuitable for: IHC-P, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
Synthetic peptide derived from an internal sequence of Human LATS2.
- HepG2 cells; Human skeletal muscle tissue.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49.1% PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride
without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab111054 was affinity-purified from Rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Our Abpromise guarantee covers the use of ab111054 in the following tested applications.
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|ICC/IF||1/100 - 1/500.|
FunctionNegative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor.
Tissue specificityExpressed at high levels in heart and skeletal muscle and at lower levels in all other tissues examined.
Sequence similaritiesBelongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 protein kinase domain.
Contains 1 UBA domain.
modificationsAutophosphorylated and phosphorylated during M-phase and the G1/S-phase of the cell cycle. Phosphorylated and activated by STK3.
Cellular localizationCytoplasm > cytoskeleton > centrosome. Cytoplasm. Cytoplasm > cytoskeleton > spindle pole. Co-localizes with STK6 at the centrosomes during interphase, early prophase and cytokinesis. Migrates to the spindle poles during mitosis, and to the midbody during cytokinesis.
- Information by UniProt
- FLJ13161 antibody
- Kinase phosphorylated during mitosis protein antibody
- KPM antibody
ab111054 at 1/100 dilution staining LATS2 in HepG2 cells by Immunofluorescence. The image on the right is treated with the synthesized peptide.
ab110541 at 1/50 dilution staining LATS2 in paraffin-embedded Human Skeletal muscle tissue by Immunohistochemistry. The image on the right is treated with the synthesized peptide.
ab111054 has been referenced in 1 publication.
- Su X et al. ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2. Biomed Pharmacother 109:788-797 (2019). PubMed: 30551532